| Prev Close | 7.87 |
| Day Low/High | 7.83 / 7.96 |
| 52 Wk Low/High | 5.46 / 10.74 |
| Avg Volume | 38.00K |
| Exchange | NASDAQ |
| Shares Outstanding | 13.14M |
| Market Cap | 103.39M |
| EPS | -0.70 |
| P/E Ratio | 11.41 |
| Div & Yield | N.A. (N.A) |
Latest News
Oramed Receives Additional $4 Million Milestone Payment From HTIT
Totaling $25.5 M in payments from HTIT received to date
Oramed Announces $6.5 Million Milestone Payment From HTIT
Payment comes in wake of positive topline phase IIB results
Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study
All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT
Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent
Patent addresses platform technology for oral insulin capsule ORMD-0801
Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal
Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.
Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China
Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share
Oramed Completes Randomization Of Over 50% Of Patients In Phase IIb Oral Insulin Study
180 Patients Expected to be Enrolled in Study
3 Stocks Under $10 to Trade for Breakouts
These under-$10 stocks are within range of triggering breakout trades.
3 Stocks Under $10 Triggering Breakout Trades
These under-$10 stocks are within range of triggering big breakout trades.
Oramed Enrolls First Patient In Its Phase IIb Oral Insulin Study
Company's largest study to date with over 30 clinical sites in the United States to participate
Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study
Company's largest study to date with over 30 clinical sites in the U.S. to participate
Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study
Company's largest study to date with over 30 clinical sites in the U.S. to participate